Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors.
Company profile
Ticker
CRBU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis ...
SEC CIK
Corporate docs
Subsidiaries
Antler Holdco, LLC • Arboreal Holdco, LLC • Biloba Holdco, LLC • Microbe Holdco, LLC ...
IRS number
453728228
CRBU stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
9 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
8-K
Regulation FD Disclosure
4 Apr 23
8-K
Regulation FD Disclosure
29 Mar 23
8-K
Regulation FD Disclosure
29 Mar 23
8-K
Other Events
24 Mar 23
S-8
Registration of securities for employees
9 Mar 23
Latest ownership filings
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.79 mm | 52.79 mm | 52.79 mm | 52.79 mm | 52.79 mm | 52.79 mm |
Cash burn (monthly) | 1.86 mm | 7.91 mm | 10.37 mm | 9.72 mm | 9.31 mm | 8.10 mm |
Cash used (since last report) | 3.57 mm | 15.12 mm | 19.83 mm | 18.59 mm | 17.81 mm | 15.49 mm |
Cash remaining | 49.22 mm | 37.67 mm | 32.96 mm | 34.20 mm | 34.98 mm | 37.30 mm |
Runway (months of cash) | 26.4 | 4.8 | 3.2 | 3.5 | 3.8 | 4.6 |
Institutional ownership, Q1 2023
82.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 123 |
Opened positions | 13 |
Closed positions | 22 |
Increased positions | 48 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 234.63 bn |
Total shares | 50.49 mm |
Total puts | 19.10 k |
Total calls | 18.10 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Partner Fund Management | 5.01 mm | $26.61 bn |
BLK Blackrock | 4.75 mm | $25.25 bn |
STT State Street | 3.36 mm | $17.82 bn |
Rachel E. Haurwitz | 3.35 mm | $37.21 mm |
Avidity Partners Management | 2.76 mm | $14.65 bn |
Rokos Capital Management | 2.75 mm | $14.09 bn |
BAC Bank Of America | 2.63 mm | $13.98 bn |
Vanguard | 2.61 mm | $13.84 bn |
Farallon Capital Partners | 2.58 mm | $41.11 mm |
Elmwood Wealth Management | 2.36 mm | $12.55 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 23 | Rachel E. Haurwitz | Common Stock | Option exercise | Acquire M | No | No | 2.96 | 10,000 | 29.60 k | 30,000 |
20 Mar 23 | Rachel E. Haurwitz | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 2.96 | 10,000 | 29.60 k | 106,350 |
21 Feb 23 | Johnson David Lee | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.12 | 21,500 | 131.58 k | 21,500 |
21 Feb 23 | Jason O'Byrne | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.12 | 131,000 | 801.72 k | 131,000 |
21 Feb 23 | Nancy Whiting | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.12 | 21,500 | 131.58 k | 21,500 |
21 Feb 23 | Braunstein Scott | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.12 | 21,500 | 131.58 k | 21,500 |
News
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $25
10 May 23
Caribou Biosciences: Q1 Earnings Insights
9 May 23
Caribou Biosciences Q1 EPS $(0.46) Beats $(0.49) Estimate
9 May 23
Stocks That Hit 52-Week Lows On Friday
28 Apr 23
Caribou Biosciences Presents New Preclinical Data On CB-012, An Allogeneic Anti-CLL-1 CAR-T Cell Therapy, At The 2023 AACR Annual Meeting
17 Apr 23
Press releases
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
9 May 23
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
8 May 23
Investigation Alert Caribou, Fate Therapeutics, Globe Life, Norfolk Southern: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
2 May 23
Caribou Biosciences to Participate in Upcoming Investor Conferences
1 May 23
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
17 Apr 23